Tearsheet

Claritev (CTEV)

Market Price (12/25/2025): $42.21 | Market Cap: $695.7 Mil
Sector: Health Care | Industry: Health Care Technology

Claritev (CTEV)

Market Price (12/25/2025): $42.21
Market Cap: $695.7 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 656%
1	Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x
2	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.5%
3	Not cash flow generative FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -12%
4	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -53%
5	Key risks CTEV key risks include [1] unsustainable leverage and solvency concerns due to high debt and ongoing net losses, Show more.

0	Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 656%
1	Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x
2	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.5%
3	Not cash flow generative FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -12%
4	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -53%
5	Key risks CTEV key risks include [1] unsustainable leverage and solvency concerns due to high debt and ongoing net losses, Show more.

Valuation, Metrics & Events

	12/25/25	2024	2023	2022	2021
Share Price CYE	$42.21
Market Cap CYE ($ Mil)	695.7	-	-	-	-
Total Debt ($ Mil)	4,652.4	4,541.2	4,567.9	4,782.4	4,926.0
Total Cash ($ Mil)	39.2	16.8	71.5	334.0	185.3
Enterprise Value ($ Mil)	5,308.9
Valuation Ratios
P/S TTM	0.7	-	-	-	-
P/EBIT TTM	-8.9	-	-	-	-
P/E TTM	-2.0	-	-	-	-
P/FCF TTM	-6.2	-	-	-	-
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/25/25	2024	2023
Share Price CYE	$42.21
Market Cap CYE ($ Mil)	695.7	-	-
Total Debt ($ Mil)	4,652.4	4,541.2	4,567.9
Total Cash ($ Mil)	39.2	16.8	71.5
Enterprise Value ($ Mil)	5,308.9
Valuation Ratios
P/S TTM	0.7	-	-
P/EBIT TTM	-8.9	-	-
P/E TTM	-2.0	-	-
P/FCF TTM	-6.2	-	-
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	CTEV	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	1.0
Rev Chg Q	6.7%	7.3%
Rev Chg LTM	0.9%	6.1%
Rev Chg 3Y Avg	-5.5%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	-0.3
Op Mgn LTM	5.2%	18.8%
CFO/Rev LTM	1.9%	20.4%
Net Inc Mgn	-35.9%	13.1%
VALUATION	VERY LOW
P/S	0.7	3.2
P/CFO	39.5	15.7
P/FCF	-6.2	20.6
P/E	-2.0	23.5
STABILITY	VERY POOR
Debt/Equity	6.69	0.21
Cash/Assets	0.01	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Contracted Healthcare Providers	1.4M	11062025	Link
Payors	140+	11062025	Link
Consumers with Access	~12.00M	11062025	Link
Employers and Other Plan Sponsors	20.00K+	11062025	Link
Claim charges processed	$43.8 billion	6302025	Link
Potential medical cost savings identified	$6.3 billion	6302025	Link

Upcoming
2/24/2026	Earnings Release	Rev: - EPS: -

CTEV Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Claritev (CTEV) experienced a decline in its stock price from late August 2025 to December 2025, with several factors contributing to its volatility. Here are some key points:

1. Negative Premarket Reaction to Q2 2025 Earnings Despite Growth: On August 6, 2025, Claritev's shares fell 2.83% in premarket trading to $38.40, despite the company reporting a return to revenue growth in its Q2 2025 earnings. While revenue increased by 3.5% year-over-year to $241.6 million, investors remained cautious due to high debt levels and ongoing challenges in its Analytics-Based services segment.

2. Wider-Than-Expected Q3 2025 Loss Despite Revenue Beat: In its Q3 2025 earnings report released on November 7, 2025, Claritev reported revenues of $246.0 million, surpassing analyst estimates. However, the company posted a wider-than-expected net loss per share of -$4.23, exceeding the estimated loss of -$3.67. While this was an improvement from the prior-year period's loss, the miss on the bottom line likely contributed to negative sentiment. The stock surged on the news, indicating a mixed market response to the results.

Show more Claritev (CTEV) experienced a decline in its stock price from late August 2025 to December 2025, with several factors contributing to its volatility. Here are some key points:

1. Negative Premarket Reaction to Q2 2025 Earnings Despite Growth: On August 6, 2025, Claritev's shares fell 2.83% in premarket trading to $38.40, despite the company reporting a return to revenue growth in its Q2 2025 earnings. While revenue increased by 3.5% year-over-year to $241.6 million, investors remained cautious due to high debt levels and ongoing challenges in its Analytics-Based services segment.

2. Wider-Than-Expected Q3 2025 Loss Despite Revenue Beat: In its Q3 2025 earnings report released on November 7, 2025, Claritev reported revenues of $246.0 million, surpassing analyst estimates. However, the company posted a wider-than-expected net loss per share of -$4.23, exceeding the estimated loss of -$3.67. While this was an improvement from the prior-year period's loss, the miss on the bottom line likely contributed to negative sentiment. The stock surged on the news, indicating a mixed market response to the results.

3. Analyst Sentiment and Profitability Concerns: As of December 1, 2025, Claritev was forecast to remain unprofitable over the next three years. Its revenue growth of 4.2% per year was projected to be slower than the US market's average of 10.7% per year. These long-term profitability concerns and slower growth projections could have put downward pressure on the stock.

4. Technical Indicators and Bearish Sentiment: As of December 19, 2025, technical indicators suggested a "Bearish" sentiment for CTEV, with 8 bullish signals and 12 bearish signals. The 50-day moving average at $52.15 was higher than the 200-day moving average at $42.99, indicating short-term bearishness as the current price lagged behind these benchmarks.

5. Share Price Volatility and Overall Performance: Claritev's stock experienced significant volatility, with a 52-week range of $6.02 to $72.58. While the stock had added about 319.2% since the beginning of 2025 versus the S&P 500's gain of 14.3% by November 7, 2025, its price as of December 22, 2025, was $42.840, and on December 19, 2025, it was trading at $41.11. This suggests a notable decline from earlier highs within its 52-week range, contributing to the -38% movement from the approximate starting point of August 31, 2025. Show less

Stock Movement Drivers

Fundamental Drivers

The -18.9% change in CTEV stock from 9/24/2025 to 12/24/2025 was primarily driven by a -20.1% change in the company's P/S Multiple.

	9242025	12242025	Change
Stock Price ($)	52.66	42.69	-18.93%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	935.54	951.00	1.65%
P/S Multiple	0.93	0.74	-20.12%
Shares Outstanding (Mil)	16.45	16.48	-0.16%
Cumulative Contribution			-18.93%

LTM = Last Twelve Months as of date shown

Market Drivers

9/24/2025 to 12/24/2025

	Return	Correlation
CTEV	-18.9%
Market (SPY)	4.4%	30.1%
Sector (XLV)	14.2%	23.8%

Fundamental Drivers

The 2.2% change in CTEV stock from 6/25/2025 to 12/24/2025 was primarily driven by a 2.5% change in the company's Total Revenues ($ Mil).

	6252025	12242025	Change
Stock Price ($)	41.79	42.69	2.15%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	927.45	951.00	2.54%
P/S Multiple	0.73	0.74	0.89%
Shares Outstanding (Mil)	16.27	16.48	-1.27%
Cumulative Contribution			2.14%

LTM = Last Twelve Months as of date shown

Market Drivers

6/25/2025 to 12/24/2025

	Return	Correlation
CTEV	2.2%
Market (SPY)	14.0%	25.5%
Sector (XLV)	16.9%	10.2%

Fundamental Drivers

null
null

Market Drivers

12/24/2024 to 12/24/2025

	Return	Correlation
CTEV
Market (SPY)	15.8%	21.0%
Sector (XLV)	13.3%	7.1%

Fundamental Drivers

null
null

Market Drivers

12/25/2023 to 12/24/2025

	Return	Correlation
CTEV
Market (SPY)	48.9%	21.0%
Sector (XLV)	18.8%	7.1%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
CTEV Return	�	�	�	�	�	�	�
Peers Return	23%	39%	-22%	31%	10%	-1%	91%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	115%
Monthly Win Rates [3]
CTEV Win Rate	�	�	�	�	�	50%
Peers Win Rate	60%	70%	37%	60%	48%	53%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
CTEV Max Drawdown	�	�	�	�	�	�
Peers Max Drawdown	-30%	-9%	-34%	-4%	-8%	-20%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: TRI, SPGI, MCO, IQV, VRSK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

CTEV has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1,100 days	1,480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Claritev (CTEV)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services, which reduce medical costs through data-driven algorithms that detect claims over-charges and recommend or negotiate reimbursement; network-based services that reduce medical costs through contracted discounts with healthcare providers; and payment and revenue integrity services, which reduce medical costs by identifying and removing improper and unnecessary charges paid during the claim. It also provides health benefit plans, which features reference-based pricing and tools to engage health plan members and providers to make the use of benefits before and after care delivery. The company serves national insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, third party administrators, bill review companies, Taft-Hartley plans, and other entities that pay medical bills in the commercial healthcare, government, workers' compensation, and auto medical markets. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

AI Analysis | Feedback

Here are 1-3 brief analogies for Claritev (CTEV):

A more focused Medtronic for the operating room.
Like the surgical instruments arm of Johnson & Johnson, but independent.
Stryker for general surgery devices.

AI Analysis | Feedback

Based on the company name "Claritev" and the common association with a leading information services provider, it is highly likely that you are referring to Clarivate Plc (NYSE: CLVT), despite the symbol "CTEV" not being associated with a major public company and likely being a typo for CLVT. Here are the major services provided by Clarivate Plc:

Web of Science: A comprehensive research platform providing curated, high-quality content for scientific and academic research, including citation data.
Derwent: Offers comprehensive patent intelligence solutions for patent search, analysis, and landscape insights to support innovation.
Cortellis: Provides critical drug and device intelligence to support pharmaceutical and biotech research, development, and commercialization decisions.
CompuMark: Delivers trademark research and brand protection services, including screening, watching, and clearance.
EndNote: A bibliographic management software that helps researchers organize references and create bibliographies.
ScholarOne: A manuscript submission and peer review tracking system used by scholarly publishers.

AI Analysis | Feedback

Clarivate (symbol: CTEV) primarily sells its data, analytics, and software solutions to other companies and institutions rather than directly to individuals.

Due to its highly diversified global customer base, Clarivate does not disclose specific individual "major customer" names in its public filings, as no single customer or group of affiliated customers accounts for 10% or more of its total revenues. Therefore, it is not possible to list specific customer companies with their symbols. Instead, its customer base consists of a broad array of organizations across various sectors, which can be categorized as follows:

Academic and Research Institutions: This includes universities, colleges, government research agencies, and other non-profit research organizations globally. They utilize Clarivate's scientific and academic research tools such as Web of Science and EndNote for discovery, analysis, and publication.
Pharmaceutical and Biotechnology Companies: Leading pharmaceutical firms, emerging biotech companies, and contract research organizations (CROs) are major users of Clarivate's drug discovery and development intelligence (e.g., Cortellis) to accelerate R&D, clinical trials, and market analysis.
Intellectual Property (IP) Professionals and Law Firms: Patent and trademark attorneys, IP departments within corporations, and specialized IP law firms rely on Clarivate's patent, trademark, and domain intelligence (e.g., Derwent, CompuMark), as well as IP management software (e.g., CPA Global), for strategy, protection, and enforcement.
Corporations: Companies across a wide range of industries utilize Clarivate's solutions for competitive intelligence, R&D strategy, innovation management, and business development insights.

AI Analysis | Feedback

Amazon (AMZN)

AI Analysis | Feedback

Travis Dalton, President & Chief Executive Officer
Travis Dalton was appointed President and Chief Executive Officer of Claritev in March 2024. He also serves as Chairman. Prior to joining Claritev, he was the General Manager & Executive Vice President of Oracle Health, where he was responsible for global growth, delivery, support, and health client accounts in 32 countries. Dalton spent over 20 years at Cerner, holding various leadership positions including President and Chief Client & Services Officer, working with commercial, global, and government clients such as the Department of Defense and Veterans Administration.

Doug Garis, Executive Vice President & Chief Financial Officer
Doug Garis leads Claritev's finance and accounting team, with expertise in FP&A, corporate strategy, capital deployment, and financial operations. Before joining Claritev, Garis served as the CFO of Oracle's largest vertical industry, Oracle Health and Life Sciences, and previously as Head of FP&A at Cerner. His career began at PwC, and he held multiple financial leadership roles at Masonite International Corporation.

Jerry Hogge, Executive Vice President & Chief Operating Officer
Jerry Hogge serves as Executive Vice President & Chief Operating Officer of Claritev, overseeing day-to-day operations to ensure clarity, alignment, and accountability, while focusing on operational efficiency and effectiveness for growth. He brings over 30 years of executive leadership experience in sales, product development, strategy, and large-scale operations.

Tiffani Misencik, Senior Vice President & Chief Growth Officer
Tiffani Misencik joined Claritev as Chief Growth Officer in October 2024. With over 25 years of experience in healthcare technology, she is responsible for sales and revenue growth strategy across all market segments, including client acquisition, client management, and market expansion. Previously, Misencik was the Chief Revenue Officer at Greenway Health and held senior leadership roles at Intelerad and Allscripts.

Mohamed Ramzy, Senior Vice President & General Manager, International
Mohamed Ramzy leads Claritev's strategy, operations, and business development for the international market and the MENA region. He has nearly 20 years of experience in healthcare technology, having most recently served as Country General Manager at Oracle Health, where he managed operations across the Arabian Gulf and Africa. His career also includes key leadership roles at Oracle Health (formerly Cerner), IMS Health, IQVIA, a Microsoft-Cisco joint venture, Roper Technologies, and CBORD.

AI Analysis | Feedback

The key risks to Claritev (CTEV) are primarily centered around its financial stability, the intensely competitive and evolving healthcare industry, and potential legal challenges.

High Debt and Financial Instability: Claritev faces significant challenges due to unsustainable leverage, high-interest costs, and ongoing net losses, which raise serious solvency and credit risk concerns. The company's debt-to-equity ratio has surged, and its shareholder equity has declined, even turning negative in recent quarters, indicating a fragile balance sheet.
Intense Competition and Industry Evolution: Operating in a fragmented and competitive market, Claritev is susceptible to pricing pressures and the need to constantly adapt to evolving industry standards and rapid technological changes in the U.S. healthcare system. The company's success is dependent on retaining key clients and the successful execution of strategic plans, such as its "Vision 2030" transformation plan, as well as its ability to successfully enter new lines of business and launch new products.
Legal Risks: Major lawsuits pose a risk to Claritev, potentially clouding the company's turnaround narrative and its future earnings visibility.

AI Analysis | Feedback

The emergence of sophisticated AI-powered platforms designed for intellectual property analysis, scientific research discovery, and competitive intelligence. These platforms, frequently developed by specialized startups or integrated into broader enterprise solutions, threaten to automate and streamline tasks traditionally performed using Clarivate’s proprietary databases and analytics tools. This could lead to more efficient, cost-effective, or integrated alternatives for clients, potentially eroding demand for Clarivate’s premium subscription services.

AI Analysis | Feedback

Claritev Corporation (CTEV) operates primarily within the U.S. healthcare industry, providing data analytics and technology-enabled solutions for cost management, payment, and revenue integrity. The addressable markets for Claritev's main products and services are as follows:

For its in-network payment and revenue integrity solutions, the total addressable market (TAM) is approximately $3 billion, for the U.S. region.
Through recent corporate and product development activities, Claritev has expanded into new markets, specifically in payor risk analytics, network transparency, and analytic services. These represent an estimated total addressable market (TAM) of $17 billion, for the U.S. region.

AI Analysis | Feedback

Claritev (CTEV) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:

International Expansion and Strategic Partnerships: Claritev is actively focusing on expanding its international presence and forming strategic partnerships. The launch of its advanced code editing solution in the UAE marks its first revenue from international expansion, and the company has also forged a strategic relationship with iO Health to bring AI-powered revenue cycle management optimization to the MENA Region.
New Annual Contract Value (ACV) and Customer Growth: The company anticipates securing approximately $60 million in new annual contract value, with 60-65% of this expected to convert to revenue in 2026. Claritev has demonstrated success in expanding its market presence by adding new clients ("5 new logos") and closing a significant number of opportunities, contributing to a 67% increase in its pipeline year-to-date. Additionally, the company has successfully renewed contracts with its top ten clients, providing stability and visibility for future growth.
Innovative Product Launches and AI-Powered Solutions: Claritev's strategic focus includes innovative product launches. Specifically, its AI-based advanced code editing (ACE) product has shown strong double-digit growth and is a solution the company aims to broadly enhance and deploy in international markets. The company leverages world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare. AI and global partnerships are also seen as drivers for monetizing higher-value healthcare solutions.
Growth in Core Service Lines: Claritev has reported significant growth across its core service lines, including a nearly 15% increase in network revenue and a 7% rise in payment revenue integrity in Q3 2025. The payment and revenue integrity service line has delivered strong quarters driven by volume growth and higher savings yield on processed claims. The analytics-based service line revenue also grew, with solid performance in core and key growth areas.
Favorable Pricing Environment and Healthcare Inflation: While the company remains cautious about the pricing and inflationary environment, its EVP and CFO has indicated that healthcare inflation and favorable pricing environments are potential tailwinds for future growth.

AI Analysis | Feedback

Share Repurchases

Claritev reported $0.0 million in share repurchases for the trailing twelve months ended June 2025.
The company did not buy back any securities in Q1 2025.

Share Issuance

As of November 3, 2025, 16,525,644 Class A common shares were outstanding.
A one-for-forty (1-for-40) reverse stock split became effective on September 20, 2024.
In Q1 2025, the company had 17,179,228 shares issued and 16,436,369 shares outstanding, compared to 16,930,827 issued and 16,187,968 outstanding in Q1 2024 (prior to the reverse stock split adjustment).

Outbound Investments

On October 27, 2025, Claritev announced a strategic investment in Klaim, Inc. to launch a co-branded Payment Acceleration Service across the U.S. and MENA regions.
On October 8, 2025, Claritev formed a strategic relationship with iO Health to introduce AI-powered Revenue Cycle Management Optimization to the MENA Region.
On May 8, 2023, Claritev (formerly MultiPlan Corp) acquired Benefits Science Technologies for $160.0 million in cash and stock consideration.

Capital Expenditures

Claritev updated its capital expenditure guidance for the full year 2025 to a range of $165 million to $175 million (as of November 7, 2025).
For the nine months ended September 30, 2025, capital expenditures totaled approximately $99.692 million.
The primary focus of capital expenditures is investing in the business to drive organic growth, supporting the company's Vision 2030 Plan through leveraging world-class technology and AI for healthcare solutions.

Better Bets than Claritev (CTEV)

INDUSTRY: Health Care Technology

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

TDOC (3.0% | 0.5x)

Teladoc Health

EVH (22.7% | 0.2x)

Evolent Health

LFMD (29.0% | 0.7x)

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

UNH (11.4% | 0.7x)

UnitedHealth

MCK (12.6% | 0.3x)

McKesson

CVS (7.7% | 0.3x)

CVS Health

ELV (8.4% | 0.4x)

Elevance Health

CI (13.6% | 0.3x)

Cigna

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CTEV: -5.5% | 14.2x)

UNH (11.4% | 11.3x)

UnitedHealth

MRK (2.9% | 11.9x)

Merck

GILD (2.3% | 14.0x)

Gilead Sciences

HCA (6.6% | 10.2x)

HCA Healthcare

BMY (1.0% | 9.8x)

Bristol-Myers Squibb

Higher Rev Chg LTM (Value for CTEV: 0.9%)

LLY (36.8%)

Eli Lilly

UNH (10.5%)

UnitedHealth

ABBV (7.4%)

AbbVie

JNJ (5.1%)

Johnson & Johnson

MRK (1.7%)

Merck

Higher Rev Chg 3Y Avg (Value for CTEV: -5.5%)

LLY (23.4%)

Eli Lilly

UNH (11.4%)

UnitedHealth

JNJ (6.1%)

Johnson & Johnson

MRK (2.9%)

Merck

ABBV (1.2%)

AbbVie

Higher Op Mgn LTM (Value for CTEV: 5.2%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

UNH (6.1%)

UnitedHealth

Higher CFO/Rev LTM (Value for CTEV: 1.9%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

UNH (4.8%)

UnitedHealth

Higher FCF/Rev LTM (Value for CTEV: -11.8%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

UNH (4.0%)

UnitedHealth

LLY (-0.1%)

Eli Lilly

Higher Total Yield (Value for CTEV: -48.6%)

MRK (10.2%)

Merck

UNH (8.6%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

GM (8.6% | 0.4x)

General Motors

F (7.8% | 0.3x)

Ford Motor

DAL (10.8% | 0.7x)

Delta Air Lines

TGT (-1.1% | 0.4x)

Target

KR (0.2% | 0.3x)

Kroger

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CTEV: -5.5% | 14.2x)

TMUS (2.4% | 11.5x)

T-Mobile US

T (1.1% | 7.3x)

AT&T

VZ (0.5% | 5.4x)

Verizon Communications

UNP (0.2% | 14.0x)

Union Pacific

LOW (-4.2% | 13.2x)

Lowe's Companies

Higher Rev Chg LTM (Value for CTEV: 0.9%)

NVDA (65.2%)

NVIDIA

MSFT (15.6%)

Microsoft

GOOGL (13.4%)

Alphabet

AMZN (10.9%)

Amazon.com

AAPL (6.0%)

Apple

Higher Rev Chg 3Y Avg (Value for CTEV: -5.5%)

NVDA (91.6%)

NVIDIA

MSFT (13.2%)

Microsoft

AMZN (11.3%)

Amazon.com

GOOGL (11.0%)

Alphabet

AAPL (1.8%)

Apple

Higher Op Mgn LTM (Value for CTEV: 5.2%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for CTEV: 1.9%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for CTEV: -11.8%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

AMZN (2.0%)

Amazon.com

Higher Total Yield (Value for CTEV: -48.6%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	CTEV	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-2.1	22.2	13.5	32.5	13.8	11.9	79.4	74.9	28.1	11.4	58.7
P/EBIT	-9.0	10.7	10.5	33.3	11.6	9.0	57.8	73.1	27.4	7.6	68.2
What You Get
Rev Chg Q	6.7%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	0.9%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	-5.5%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	0.2%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Is Claritev Stock Built to Withstand More Downside?	Return

	Title
0	ARTICLES

Trade Ideas

Select ideas related to CTEV. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	20.9%	20.9%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	13.5%	13.5%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	1.6%	1.6%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	11.8%	11.8%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OMER	Omeros	0.9	75.5%	55.5%
DVAX	Dynavax Technologies	1.8	38.2%	20.4%
EWTX	Edgewise Therapeutics	2.9	25.5%	2.2%
AGIO	Agios Pharmaceuticals	1.7	18.6%	-11.2%
TVTX	Travere Therapeutics	3.6	13.9%	131.2%
KOD	Kodiak Sciences	1.6	13.2%	212.4%
RZLT	Rezolute	0.3	13.2%	-44.1%
UP	Wheels Up Experience	0.5	11.7%	-57.4%
FBYD	Falcons Beyond Global	0.7	9.5%	129.7%
BW	Babcock & Wilcox Enterprises	0.5	8.5%	226.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ASTS	AST SpaceMobile	18.9	-8.9%	269.9%
QBTS	D-Wave Quantum	9.4	-5.5%	227.6%
NNE	Nano Nuclear Energy	1.2	-4.6%	21.7%
MNMD	Mind Medicine	1.2	-4.2%	93.0%
PPTA	Perpetua Resources	2.0	-4.0%	149.1%
KOS	Kosmos Energy	0.4	-4.0%	-73.6%
FRMI	Fermi	5.5	-4.0%	-75.7%
EXOD	Exodus Movement	0.4	-3.9%	-50.5%
TLRY	Tilray Brands	10.8	-3.6%	-23.7%
AEHR	Aehr Test Systems	0.7	-3.1%	32.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	74.0%	55.5%
LUNR	Intuitive Machines	2.0	63.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	51.1%	11.2%
FBYD	Falcons Beyond Global	0.7	47.2%	129.7%
FLY	Firefly Aerospace	3.8	45.9%	-55.2%
RKLB	Rocket Lab	39.8	43.0%	203.0%
DVAX	Dynavax Technologies	1.8	42.5%	20.4%
UAMY	United States Antimony	0.8	39.9%	258.8%
DJT	Trump Media & Technology	4.0	36.7%	-58.0%
RZLT	Rezolute	0.3	36.3%	-44.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	31.7	-80.5%	-28.0%
TPL	Texas Pacific Land	6.8	-66.5%	-19.2%
LW	Lamb Weston	6.0	-28.6%	-34.8%
TLRY	Tilray Brands	10.8	-21.2%	-23.7%
INSP	Inspire Medical Systems	2.8	-19.1%	-48.4%
TDUP	ThredUp	0.8	-17.1%	354.7%
OLMA	Olema Pharmaceuticals	2.3	-15.8%	370.8%
IIPR	Innovative Industrial Properties	1.4	-12.9%	-15.7%
ABM	ABM Industries	2.6	-12.6%	-15.8%
FRMI	Fermi	5.5	-12.6%	-75.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	3.0	144.6%	47.5%
TE	T1 Energy	1.1	124.5%	418.4%
ANF	Abercrombie & Fitch	6.0	93.2%	-15.2%
VERA	Vera Therapeutics	3.6	90.4%	31.6%
LUNR	Intuitive Machines	2.0	85.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	82.5%	11.2%
RKLB	Rocket Lab	39.8	81.8%	203.0%
PL	Planet Labs PBC	6.2	76.1%	403.0%
NRGV	Energy Vault	0.8	66.9%	118.9%
FLY	Firefly Aerospace	3.8	60.4%	-55.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-44.1%
JANX	Janux Therapeutics	0.9	-54.6%	-73.3%
LENZ	LENZ Therapeutics	0.5	-46.3%	-40.6%
FRMI	Fermi	5.5	-45.2%	-75.7%
GOGO	Gogo	0.6	-34.1%	-43.0%
HPK	HighPeak Energy	0.6	-30.8%	-69.2%
ORIC	ORIC Pharmaceuticals	0.7	-28.5%	4.5%
FDMT	4D Molecular Therapeutics	0.5	-25.6%	45.4%
NKTR	Nektar Therapeutics	0.6	-25.1%	215.0%
LW	Lamb Weston	6.0	-24.8%	-34.8%

Peer Comparisons for Claritev

Peers to compare with:

Financials

	CTEV	TRI	SPGI	MCO	IQV	VRSK	Median
Name	Claritev	Thomson .	S&P Glob.	Moodys	IQVIA	Verisk A.
Mkt Price	42.69	133.00	525.74	517.28	226.02	218.85	222.44
Mkt Cap	0.7	59.8	160.0	92.5	38.5	30.5	49.1
Rev LTM	951	7,376	15,012	7,501	15,904	3,030	7,438
Op Inc LTM	50	2,128	6,031	3,286	2,258	1,347	2,193
FCF LTM	-113	1,822	5,461	2,398	2,211	1,116	2,016
FCF 3Y Avg	2	1,869	4,657	2,166	1,831	942	1,850
CFO LTM	18	2,459	5,643	2,717	2,804	1,348	2,588
CFO 3Y Avg	119	2,456	4,805	2,470	2,448	1,179	2,452

Growth & Margins

	CTEV	TRI	SPGI	MCO	IQV	VRSK	Median
Name	Claritev	Thomson .	S&P Glob.	Moodys	IQVIA	Verisk A.
Rev Chg LTM	0.9%	3.0%	9.0%	8.8%	3.8%	7.3%	5.6%
Rev Chg 3Y Avg	-5.5%	3.9%	13.3%	9.8%	3.6%	13.4%	6.9%
Rev Chg Q	6.7%	3.4%	8.8%	10.7%	5.2%	5.9%	6.3%
QoQ Delta Rev Chg LTM	1.7%	0.8%	2.1%	2.7%	1.3%	1.4%	1.5%
Op Mgn LTM	5.2%	28.9%	40.2%	43.8%	14.2%	44.4%	34.5%
Op Mgn 3Y Avg	12.5%	26.9%	36.3%	40.7%	13.8%	43.6%	31.6%
QoQ Delta Op Mgn LTM	-1.5%	2.3%	1.0%	1.3%	-0.2%	0.5%	0.7%
CFO/Rev LTM	1.9%	33.3%	37.6%	36.2%	17.6%	44.5%	34.8%
CFO/Rev 3Y Avg	12.6%	34.6%	34.8%	36.8%	15.9%	41.6%	34.7%
FCF/Rev LTM	-11.8%	24.7%	36.4%	32.0%	13.9%	36.8%	28.3%
FCF/Rev 3Y Avg	0.2%	26.4%	33.7%	32.2%	11.9%	33.2%	29.3%

Valuation

	CTEV	TRI	SPGI	MCO	IQV	VRSK	Median
Name	Claritev	Thomson .	S&P Glob.	Moodys	IQVIA	Verisk A.
Mkt Cap	0.7	59.8	160.0	92.5	38.5	30.5	49.1
P/S	0.7	8.1	10.7	12.3	2.4	10.1	9.1
P/EBIT	-9.0	25.2	26.0	28.2	16.7	22.6	23.9
P/E	-2.1	34.0	37.9	41.2	30.0	33.1	33.6
P/CFO	39.9	24.3	28.4	34.1	13.7	22.6	26.3
Total Yield	-48.6%	4.6%	3.4%	3.2%	3.3%	3.8%	3.3%
Dividend Yield	0.0%	1.7%	0.7%	0.7%	0.0%	0.8%	0.7%
FCF Yield 3Y Avg	-	2.8%	3.3%	2.9%	5.0%	2.6%	2.9%
D/E	6.6	0.0	0.1	0.1	0.4	0.2	0.1
Net D/E	6.6	0.0	0.1	0.1	0.3	0.1	0.1

Returns

	CTEV	TRI	SPGI	MCO	IQV	VRSK	Median
Name	Claritev	Thomson .	S&P Glob.	Moodys	IQVIA	Verisk A.
1M Rtn	-11.2%	0.4%	7.5%	8.0%	-0.9%	-0.2%	0.1%
3M Rtn	-18.9%	-15.3%	7.3%	9.2%	24.7%	-9.7%	-1.2%
6M Rtn	2.2%	-31.5%	1.2%	7.8%	42.4%	-27.8%	1.7%
12M Rtn	-	-17.3%	4.9%	8.5%	13.0%	-20.9%	4.9%
3Y Rtn	-	22.5%	61.9%	90.2%	10.9%	27.0%	27.0%
1M Excs Rtn	-14.6%	-3.0%	4.1%	4.7%	-4.3%	-3.6%	-3.3%
3M Excs Rtn	-19.3%	-20.4%	3.7%	4.7%	23.0%	-15.1%	-5.7%
6M Excs Rtn	-13.0%	-44.9%	-10.4%	-5.1%	30.0%	-40.9%	-11.7%
12M Excs Rtn	-	-33.7%	-9.2%	-5.1%	-2.3%	-37.3%	-9.2%
3Y Excs Rtn	-	-57.4%	-21.0%	9.0%	-68.5%	-52.8%	-52.8%

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/7/2025	2/26/2025	2/29/2024	3/1/2023	2/25/2022	3/16/2021	2/25/2022
Key Financials
Total Revenue	951	931	962	1,080	1,118	938	983
EBITDA	368	-1,008	652	158	815	192	786
Operating Income	50	99	170	334	386	-132	368
Net Income	-342	-1,646	-92	-573	102	-521	10
EPS	-20.91	-101.92	-5.69	-36.00	6.40	-44.40	0.35
Growth Rates
Total Revenue Growth	0.9%	-3.2%	-10.9%	-3.4%	19.2%	-4.6%	-5.6%
EBITDA Growth	143.1%	-254.6%	311.8%	-80.6%	323.6%	-75.5%	-3.4%
Operating Income Growth	-60.9%	-41.8%	-49.1%	-13.5%	392.9%	-135.8%	-13.9%
Net Income Growth	77.8%	-1694.9%	84.0%	-661.2%	119.6%	-5461.1%	-73.2%
Margins
EBITDA Margin	38.6%	-108.3%	67.8%	14.7%	72.9%	20.5%	80.0%
Operating Income Margin	5.2%	10.6%	17.7%	31.0%	34.5%	-14.1%	37.5%
Net Income Margin	-35.9%	-176.9%	-9.5%	-53.1%	9.1%	-55.5%	1.0%
Cash & Debt
Total Cash	39	17	72	334	185	127	22
Total Debt	4,652	4,541	4,568	4,782	4,926	4,612	5,430
Net Debt / (Cash)	4,613	4,524	4,496	4,448	4,741	4,486	5,408
Cash Flows
Net Cash from Operations	18	108	172	372	405	377	284
Free Cash from Operations	-113	-11	63	283	320	307	218
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	10	15	-0	100	101	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/7/2025	8/7/2025	5/9/2025	2/26/2025	11/6/2024	8/2/2024	5/9/2024	2/29/2024	11/8/2023	8/3/2023	5/10/2023	3/1/2023
Key Financials Quarterly
Total Revenue	246	242	231	232	230	233	235	244	243	238	237	241
Ebitda	120	129	113	5	-227	-414	-371	159	160	142	190	-462
Operating Income	10	17	10	13	23	30	33	41	40	42	48	52
Net Income	-70	-63	-71	-138	-391	-577	-540	-31	-24	-36	0	-650
EPS	-4.23	-3.81	-4.38	-8.49	-24.25	-35.78	-33.40	-1.94	-1.49	-2.40	0.01	-40.80
Key Financials TTM
Total Revenue TTM	951	936	927	931	943	955	959	962	958	966	1,018	1,080
Ebitda TTM	368	20	-523	-1,008	-854	-466	91	652	31	61	115	158
Operating Income TTM	50	63	76	99	127	143	155	170	181	205	263	334
Net Income TTM	-342	-663	-1,177	-1,646	-1,539	-1,172	-632	-92	-710	-667	-617	-573
Growth Rates Quarterly
Total Revenue Growth	6.7%	3.5%	-1.4%	-4.9%	-5.1%	-1.9%	-0.9%	1.3%	-3.1%	-18.0%	-20.6%	-19.2%
EBITDA Growth	153.0%	131.1%	130.5%	-96.9%	-241.8%	-391.1%	-295.3%	134.5%	-15.8%	-27.6%	-18.5%	-320.4%
Operating Income Growth	-57.0%	-44.3%	-70.1%	-67.8%	-41.2%	-28.3%	-32.0%	-21.5%	-37.6%	-58.2%	-59.8%	-48.9%
Net Income Growth	82.2%	89.1%	86.8%	-339.5%	-1521.2%	-1485.7%	-258324.4%	95.2%	-222.3%	-369.2%	-99.5%	-2707.0%
Margins Quarterly
EBITDA Margin	49.0%	53.3%	49.0%	2.1%	-98.6%	-177.4%	-158.3%	65.2%	66.0%	59.8%	80.3%	-191.5%
Operating Income Margin	4.1%	6.9%	4.2%	5.7%	10.2%	12.8%	13.9%	16.7%	16.4%	17.4%	20.3%	21.6%
Net Income Margin	-28.4%	-25.9%	-30.8%	-59.4%	-169.8%	-247.0%	-230.1%	-12.9%	-9.9%	-15.3%	0.1%	-269.7%
Cash & Debt
Total Cash	39	56	23	17	87	49	59	72	101	90	266	334
Total Debt	4,652	4,649	4,632	4,541	4,538	4,543	4,545	4,568	4,595	4,642	4,643	4,782
Net Debt / (Cash)	4,613	4,593	4,609	4,524	4,451	4,495	4,486	4,496	4,493	4,552	4,378	4,448
Cash Flows Quarterly
FCF from Operations	20	61	-30	-33	73	18	50	28	72	8	64	28
Cash Flows TTM
FCF from Operations TTM	18	71	28	108	169	168	157	172	172	209	242	372
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	10	2	-0	7	6	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	0.4%	0.7%	0.5%	0.6%	1.3%	1.7%	1.9%	2.4%	1.9%	2.0%	0.3%	3.3%
Return on Invested Capital (ROIC) TTM
ROIC TTM	0.6%	0.8%	1.0%	1.4%	1.8%	2.1%	2.2%	2.2%	2.7%	3.0%	4.2%	5.2%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Analytics-Based Services	626	714	709	565	562
Network-Based Services	223	245	278	271	315
Payment and Revenue Integrity Services	112	121	130	102	107
Total	962	1,080	1,118	938	983

Price Behavior

Price Behavior

Market Price	$42.69
Market Cap ($ Bil)	0.7
First Trading Date	02/14/2020
Distance from 52W High	-41.2%
	50 Days	200 Days
DMA Price	$31.84	$31.84
DMA Trend	up	down
Distance from DMA	34.1%	34.1%
	3M	1YR
Volatility	108.8%	95.2%
Downside Capture	225.61	108.10
Upside Capture	82.39	170.76
Correlation (SPY)	29.6%

CTEV Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	3.29	2.45	2.07	2.09	0.13	0.26
Up Beta	-6.20	-1.84	-0.90	2.02	-0.19	-0.30
Down Beta	9.33	8.40	6.85	5.20	-0.14	0.59
Up Capture	381%	141%	6%	123%	185%	21%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	9	22	31	66	102	102
Down Capture	505%	130%	147%	51%	65%	43%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	9	18	30	57	82	82

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/7/2025	11.8%	-28.7%	-45.1%
8/6/2025	29.4%	66.2%	71.2%
5/8/2025	1.6%	26.5%	86.3%
2/25/2025		�	�
11/5/2024
8/1/2024
2/29/2024
11/7/2023
...
SUMMARY STATS
# Positive	3	3	3
# Negative	14	14	14
Median Positive	11.8%	46.4%	78.8%
Median Negative		-28.7%	-45.1%
Max Positive	29.4%	66.2%	86.3%
Max Negative		-28.7%	-45.1%

	Forward Returns
11/7/2025	11.8%	-28.7%	-45.1%
8/6/2025	29.4%	66.2%	71.2%
5/8/2025	1.6%	26.5%	86.3%
2/25/2025		�	�
11/5/2024
8/1/2024
2/29/2024
11/7/2023
8/2/2023
2/28/2023
11/8/2022
8/4/2022
5/10/2022
2/17/2022
11/3/2021
3/10/2021
10/19/2020
SUMMARY STATS
# Positive	3	3	3
# Negative	14	14	14
Median Positive	11.8%	46.4%	78.8%
Median Negative		-28.7%	-45.1%
Max Positive	29.4%	66.2%	86.3%
Max Negative		-28.7%	-45.1%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11072025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	5092025	10-Q 3/31/2025
12312024	2262025	10-K 12/31/2024
9302024	11062024	10-Q 9/30/2024
6302024	8022024	10-Q 6/30/2024
3312024	5092024	10-Q 3/31/2024
12312023	2292024	10-K 12/31/2023
9302023	11082023	10-Q 9/30/2023
6302023	8032023	10-Q 6/30/2023
3312023	5102023	10-Q 3/31/2023
12312022	3012023	10-K 12/31/2022
9302022	11092022	10-Q 9/30/2022
6302022	8052022	10-Q 6/30/2022
3312022	5102022	10-Q 3/31/2022
12312021	2252022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Claritev (CTEV)

Market Price (12/25/2025): $42.21 | Market Cap: $695.7 MilSector: Health Care | Industry: Health Care Technology

Claritev (CTEV)

Market Price (12/25/2025): $42.21Market Cap: $695.7 MilSector: Health CareIndustry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

CTEV Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Claritev (CTEV)

Interactive Breakdown

Better Bets than Claritev (CTEV)

INDUSTRY: Health Care Technology

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CTEV: -5.5% | 14.2x)

Higher Rev Chg LTM (Value for CTEV: 0.9%)

Higher Rev Chg 3Y Avg (Value for CTEV: -5.5%)

Higher Op Mgn LTM (Value for CTEV: 5.2%)

Higher CFO/Rev LTM (Value for CTEV: 1.9%)

Higher FCF/Rev LTM (Value for CTEV: -11.8%)

Higher Total Yield (Value for CTEV: -48.6%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CTEV: -5.5% | 14.2x)

Higher Rev Chg LTM (Value for CTEV: 0.9%)

Higher Rev Chg 3Y Avg (Value for CTEV: -5.5%)

Higher Op Mgn LTM (Value for CTEV: 5.2%)

Higher CFO/Rev LTM (Value for CTEV: 1.9%)

Higher FCF/Rev LTM (Value for CTEV: -11.8%)

Higher Total Yield (Value for CTEV: -48.6%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for CTEV: -5.5% | 0.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for CTEV: -5.5% | 14.2x)

Higher Rev Chg LTM (Value for CTEV: 0.9%)

Higher Rev Chg 3Y Avg (Value for CTEV: -5.5%)

Higher Op Mgn LTM (Value for CTEV: 5.2%)

Higher CFO/Rev LTM (Value for CTEV: 1.9%)

Higher FCF/Rev LTM (Value for CTEV: -11.8%)

Higher Total Yield (Value for CTEV: -48.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Claritev

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Market Price (12/25/2025): $42.21 | Market Cap: $695.7 Mil
Sector: Health Care | Industry: Health Care Technology

Market Price (12/25/2025): $42.21
Market Cap: $695.7 Mil
Sector: Health Care
Industry: Health Care Technology